- Home
- VTYX vs CRTO Comparison
VTYX vs CRTO Comparison
Compare VTYX & CRTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VTYX | CRTO |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Advertising |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 990.9M | 1.1B |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | VTYX | CRTO |
|---|---|---|
| Price | $13.98 | $20.70 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 9 |
| Target Price | $13.50 | ★ $38.44 |
| AVG Volume (30 Days) | ★ 5.9M | 572.0K |
| Earning Date | 02-26-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 83.79 |
| EPS | N/A | ★ 3.00 |
| Revenue | N/A | ★ $1,956,800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.42 |
| P/E Ratio | ★ N/A | $6.77 |
| Revenue Growth | N/A | ★ 0.53 |
| 52 Week Low | $0.78 | $19.00 |
| 52 Week High | $25.00 | $47.27 |
Technical Indicators
Market Signals| Indicator | VTYX | CRTO |
|---|---|---|
| Relative Strength Index (RSI) | 75.73 | 53.61 |
| Support Level | $7.08 | $19.02 |
| Resistance Level | $14.07 | $21.55 |
| Average True Range (ATR) | 0.27 | 0.87 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 83.47 | 66.91 |
Price Performance
Historical ComparisonAbout VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About CRTO Criteo S.A.
Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.